Franklin Resources
CRNX icon

Franklin Resources’s Crinetics Pharmaceuticals CRNX Stock Holding History

Franklin Resources’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$680K Buy
18,735
+1,064
+6% +$47.5K ﹤0.01% 2349
2025
Q4 		$823K Sell
17,671
-2,729
-13% -$121K ﹤0.01% 2183
2025
Q3 		$850K Sell
20,400
-628,738
-97% -$20.1M ﹤0.01% 2193
2025
Q2 		$18.7M Sell
649,138
-314,143
-33% -$9.7M ﹤0.01% 949
2025
Q1 		$32.3M Sell
963,281
-628,385
-39% -$23.5M 0.01% 747
2024
Q4 		$81.4M Buy
1,591,666
+201,556
+14% +$11.3M 0.02% 467
2024
Q3 		$73.8M Buy
1,390,110
+528,688
+61% +$27.3M 0.02% 479
2024
Q2 		$38.6M Buy
861,422
+448,213
+108% +$20.7M 0.01% 635
2024
Q1 		$19.3M Hold
413,209
– – 0.01% 881
2023
Q4 		$14.7M Buy
413,209
+274,384
+198% +$8.41M 0.01% 839
2023
Q3 		$4.13M Buy
138,825
+34
+0% +$701 ﹤0.01% 1143
2023
Q2 		$2.5M Buy
138,791
+261
+0.2% +$5.21K ﹤0.01% 1332
2023
Q1 		$2.22M Buy
+138,530
New +$2.56M ﹤0.01% 1333

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Franklin Resources's CRNX Position: Q1 2026 in Review

Franklin Resources increased its Crinetics Pharmaceuticals (CRNX) stake by 6% in Q1 2026, buying an estimated $47.5K and bringing the position to 18,735 shares worth $680K. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

Franklin Resources first reported a position in CRNX in Q1 2023 and has held it in 13 quarters since. The position peaked at $81.4M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Franklin Resources held 18,735 shares of Crinetics Pharmaceuticals worth $680K as of Q1 2026.
  • Franklin Resources bought 1,064 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $47.5K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Franklin Resources's portfolio in Q1 2026, its #2349 holding.
  • Franklin Resources first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Franklin Resources's Crinetics Pharmaceuticals position peaked at $81.4M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.